Based on research from the universities of Bristol and Nottingham, Exonate has now raised $9m to develop a topical eye drop for conditions including diabetic macular edema.
Exonate, a UK-based macular degeneration medication developer based on research from the universities of Bristol and Nottingham, has closed a £1.5m ($1.9m) round backed by University of Bristol’s Enterprise Fund (UBEF) and multi-university venture fund Uniseed, according to Eyewire.
Martlet, the corporate angel investment division of aerospace, defence and property group Marshall of Cambridge, also invested along with Angel CoFund, Wren Capital, O2h Ventures and undisclosed angel investors.
UBEF is a co-investment vehicle launched by University of Bristol…
